◆英語タイトル:Crescita Therapeutics Inc (CTX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013134
◆発行会社(調査会社):
GlobalData
◆発行日:2017年11月27日
◆ページ数:40
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:カナダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
Crescita Therapeutics Inc (Crescita Therapeutics) develops products for the treatment of skin diseases and their symptoms. The company’s product portfolio includes over-the-counter and prescription products such as topical creams. It offers pliaglis, a local anesthetic cream for superficial dermatological and cosmetic procedures. Crescita Therapeutics along with Ferndale Laboratories, Inc. develops Mical (1) and Mical (2) for the therapeutic areas of psoriasis and dermatological skin treatment, respectively. Mical (1) is in Phase 1 clinical trials and and Mical (2) is in preclinical stage of development. The company develops products using drug delivery platform that include multiplexed molecular penetration enhancers (MMPE) and DuraPeel. Crescita Therapeutics is headquartered in Mississauga, Ontario, Canada.
Crescita Therapeutics Inc (CTX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Crescita Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Crescita Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Crescita Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Crescita Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Crescita Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Crescita Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
INTEGA Skin Sciences Acquires Alyria Skincare Product Line from Sanofi Consumer Health for USD1.3 Million 10
Licensing Agreements 11
Taro Pharma Enters into Licensing Agreement with Crescita Therapeutics 11
Dermatological Contract Research Company Enters into Licensing Agreement with Crescita Therapeutics 12
Knight Therapeutics Enters into Licensing Agreement with INTEGA Skin Sciences 13
Debt Offering 14
Crescita Therapeutics Raises USD0.7 Million in Private Placement of 9% Convertible Debenture 14
Asset Transactions 15
Crescita Therapeutics Divests Manufacturing Facility in Germany 15
Acquisition 16
Knight Therapeutics Acquires 4% Stake in Crescita Therapeutics 16
Crescita Therapeutics Acquires Intega Skin Sciences for USD7.6 Million 17
Crescita Therapeutics Inc – Key Competitors 18
Crescita Therapeutics Inc – Key Employees 19
Crescita Therapeutics Inc – Locations And Subsidiaries 20
Head Office 20
Other Locations & Subsidiaries 20
Recent Developments 21
Financial Announcements 21
Nov 10, 2017: Crescita Therapeutics Announces 2017 Third Quarter Results and Appoints New CFO 21
Aug 14, 2017: Crescita Therapeutics Announces Profitable 2017 Second Quarter Results 23
May 15, 2017: Crescita Therapeutics Announces 2017 First Quarter Results 25
Mar 30, 2017: Crescita Therapeutics Announces 2016 Fourth Quarter and Year-End Results 27
Nov 14, 2016: Crescita Therapeutics Announces 2016 Third Quarter Results 29
Jul 27, 2016: Crescita Therapeutics Announces 2016 Second Quarter Results 30
May 10, 2016: Crescita Therapeutics Announces 2016 First Quarter Results 32
Corporate Communications 34
Apr 12, 2017: Crescita Therapeutics Announces the Appointment of a New President 34
Feb 10, 2017: Crescita Therapeutics Announces Management and Board Changes 35
Nov 03, 2016: Crescita Appoints Dan Chicoine as Interim CEO 36
Sep 29, 2016: Crescita Therapeutics Announces Changes to the Board of Directors 37
Product News 38
Jan 26, 2017: Crescita Therapeutics Announces Launch of ISDIN Product Line at Brunet Pharmacy 38
Other Significant Developments 39
Mar 07, 2016: Crescita Therapeutics Provides Corporate Update 39
Appendix 40
Methodology 40
About GlobalData 40
Contact Us 40
Disclaimer 40
List of Tables
Crescita Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Crescita Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Crescita Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Crescita Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Crescita Therapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Crescita Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
INTEGA Skin Sciences Acquires Alyria Skincare Product Line from Sanofi Consumer Health for USD1.3 Million 10
Taro Pharma Enters into Licensing Agreement with Crescita Therapeutics 11
Dermatological Contract Research Company Enters into Licensing Agreement with Crescita Therapeutics 12
Knight Therapeutics Enters into Licensing Agreement with INTEGA Skin Sciences 13
Crescita Therapeutics Raises USD0.7 Million in Private Placement of 9% Convertible Debenture 14
Crescita Therapeutics Divests Manufacturing Facility in Germany 15
Knight Therapeutics Acquires 4% Stake in Crescita Therapeutics 16
Crescita Therapeutics Acquires Intega Skin Sciences for USD7.6 Million 17
Crescita Therapeutics Inc, Key Competitors 18
Crescita Therapeutics Inc, Key Employees 19
Crescita Therapeutics Inc, Subsidiaries 20